RESUMO
We have tested the effects of an mAb directed against the protein core of the extracellular domain of the human EGF receptor (mAb108), on the binding of EGF, and on the early responses of cells to EGF presentation. We used NIH 3T3 cells devoid of murine EGF receptor, transfected with a cDNA encoding the full-length human EGF receptor gene, and fully responsive to EGF. The binding to saturation of mAb108 to the surface of these cells at 4 degrees C and at other temperatures specifically reduced high-affinity binding of EGF, but did not change the dissociation constant or the estimated number of binding sites for low-affinity binding of EGF. The kinetics of EGF binding to the transfected cells were measured to determine the effects of the mAb on the initial rate of EGF binding at 37 degrees C. Interestingly, high-affinity EGF receptor bound EGF with an intrinsic on-rate constant 40-fold higher (9.8 x 10(6) M-1.s-1) than did low-affinity receptor (2.5 x 10(5) M-1.s-1), whereas the off-rate constants, measured at 4 degrees C were similar. Cells treated with the mAb or with phorbol myristate acetate displayed single on-rate constants similar to that for the low-affinity receptors. At low doses of EGF ranging from 0.4 to 1.2 nM, pretreatment of cells with mAb108 inhibited by 50-100% all of the early responses tested, including stimulation of tyrosine-specific phosphorylation of the EGF receptor, turnover of phosphatidyl inositol, elevation of cytoplasmic pH, and release of Ca2+ from intracellular stores. At saturating doses of EGF (20 nM) the inhibition of these early responses by prebinding of mAb108 was overcome. On the basis of these results, we propose that the high-affinity EGF receptors are necessary for EGF receptor signal transduction.
Assuntos
Anticorpos Monoclonais/imunologia , Fator de Crescimento Epidérmico/imunologia , Animais , Anticorpos Monoclonais/análise , Especificidade de Anticorpos , Cálcio/metabolismo , Relação Dose-Resposta a Droga , Fator de Crescimento Epidérmico/farmacocinética , Fator de Crescimento Epidérmico/farmacologia , Receptores ErbB/metabolismo , Hibridomas/imunologia , Hibridomas/metabolismo , Hibridomas/ultraestrutura , Concentração de Íons de Hidrogênio , Fosfatos de Inositol/metabolismo , Cinética , Camundongos , Mieloma Múltiplo/imunologia , Mieloma Múltiplo/metabolismo , Mieloma Múltiplo/patologia , Ésteres de Forbol/metabolismo , Fosforilação , Temperatura , Células Tumorais Cultivadas/imunologia , Células Tumorais Cultivadas/metabolismo , Células Tumorais Cultivadas/ultraestruturaRESUMO
Epidermal growth factor (EGF) receptor was affinity labeled with 125I-labeled EGF, using bifunctional covalent cross-linking agents. The affinity-labeled receptor was isolated and cleaved with CNBr to yield a single-labeled fragment, which was unequivocally identified by site-specific antibodies and other methods to encompass residues 294 to 543 of the EGF receptor. On the basis of amino acid sequence conservation, the extracellular portion of EGF receptor can be divided into four domains. The labeled CNBr fragment contains the entire sequence which is flanked by the two cysteine-rich domains of extracellular portion of the EGF receptor denoted as domain III. On the basis of these and other results, we propose that domain III contributes most of the interactions that define ligand-binding specificity of the EGF receptor.
Assuntos
Marcadores de Afinidade/metabolismo , Fator de Crescimento Epidérmico/metabolismo , Receptores ErbB/metabolismo , Succinimidas/metabolismo , Anticorpos , Linhagem Celular , Reagentes de Ligações Cruzadas/metabolismo , Brometo de Cianogênio , Cisteína , Receptores ErbB/imunologia , Humanos , Radioisótopos do Iodo , Metionina , Fragmentos de Peptídeos/metabolismo , Radioisótopos de EnxofreRESUMO
Epidermal growth factor (EGF) treatment of NIH 3T3 cells transfected with wild-type EGF receptor induced tyrosine phosphorylation of phospholipase C-gamma (PLC-gamma). The EGF receptor and PLC-gamma were found to be physically associated such that antibodies directed against PLC-gamma or the EGF receptor coimmunoprecipitated both proteins. The association between PLC-gamma and wild-type EGF receptor was dependent on the concentration of EGF, but EGF did not enhance the association between PLC-gamma and a kinase-negative mutant of the EGF receptor. Oligomerization of the EGF receptor was not sufficient to induce association of the EGF receptor with PLC-gamma, since the kinase-negative mutant receptor underwent normal dimerization in response to EGF yet did not associate with PLC-gamma. The form of PLC-gamma associated with the EGF receptor appeared to be primarily the non-tyrosine-phosphorylated form. It is concluded that the kinase activity of the EGF receptor is essential for association of PLC-gamma with the EGF receptor, possibly by stimulating receptor autophosphorylation.
Assuntos
Receptores ErbB/metabolismo , Proteínas Tirosina Quinases/metabolismo , Transfecção , Fosfolipases Tipo C/metabolismo , Animais , Células Cultivadas , Fator de Crescimento Epidérmico/farmacologia , Receptores ErbB/genética , Expressão Gênica , Genes , Humanos , Cinética , Camundongos , Camundongos Endogâmicos , Mutação , Fosforilação , Proteínas Tirosina Quinases/genéticaRESUMO
Phospholipase C-gamma (PLC-gamma) is a substrate of the fibroblast growth factor receptor (FGFR; encoded by the flg gene) and other receptors with tyrosine kinase activity. It has been demonstrated that the src homology region 2 (SH2 domain) of PLC-gamma and of other signalling molecules such as GTPase-activating protein and phosphatidylinositol 3-kinase-associated p85 direct their binding toward tyrosine-autophosphorylated regions of the epidermal growth factor or platelet-derived growth factor receptor. In this report, we describe the identification of Tyr-766 as an autophosphorylation site of flg-encoded FGFR by direct sequencing of a tyrosine-phosphorylated tryptic peptide isolated from the cytoplasmic domain of FGFR expressed in Escherichia coli. The same phosphopeptide was found in wild-type FGFR phosphorylated either in vitro or in living cells. Like other growth factor receptors, tyrosine-phosphorylated wild-type FGFR or its cytoplasmic domain becomes associated with intact PLC-gamma or with a fusion protein containing the SH2 domain of PLC-gamma. To delineate the site of association, we have examined the capacity of a 28-amino-acid tryptic peptide containing phosphorylated Tyr-766 to bind to various constructs containing SH2 and other domains of PLC-gamma. It is demonstrated that the tyrosine-phosphorylated peptide binds specifically to the SH2 domain but not to the SH3 domain or other regions of PLC-gamma. Hence, Tyr-766 and its flanking sequences represent a major binding site in FGFR for PLC-gamma. Alignment of the amino acid sequences surrounding Tyr-766 with corresponding regions of other FGFRs revealed conserved tyrosine residues in all known members of the FGFR family. We propose that homologous tyrosine-phosphorylated regions in other FGFRs also function as binding sites for PLC-gamma and therefore are involved in coupling to phosphatidylinositol breakdown.
Assuntos
Receptores de Superfície Celular/metabolismo , Fosfolipases Tipo C/metabolismo , Sequência de Aminoácidos , Sequência de Bases , Sítios de Ligação , Clonagem Molecular , Escherichia coli/metabolismo , Proteínas Filagrinas , Humanos , Dados de Sequência Molecular , Fosforilação , Testes de Precipitina , Receptores de Fatores de Crescimento de Fibroblastos , Alinhamento de Sequência , Fagos T/metabolismo , Tirosina/metabolismoRESUMO
The primary structure of the chicken epidermal growth factor (EGF) receptor was deduced from the sequence of a cDNA clone containing the complete coding sequence and shown to be highly homologous to the human EGF receptor. NIH-3T3 cells devoid of endogenous EGF receptor were transfected with the appropriate cDNA constructs and shown to express either chicken or human EGF receptors. Like the human EGF receptor, the chicken EGF receptor is a glycoprotein with an apparent molecular weight of 170,000. Murine EGF bound to the chicken receptor with approximately 100-fold lower affinity than to the human receptor molecule. Surprisingly, human transforming growth factor alpha (TGF-alpha) bound equally well or even better to the chicken EGF receptor than to the human EGF receptor. Moreover, TGF-alpha stimulated DNA synthesis 100-fold better than did EGF in NIH 3T3 cells that expressed the chicken EGF receptor. The differential binding and potency of mammalian EGF and TGF-alpha by the avian EGF receptor contrasts with the similar affinities of the mammalian receptor for the two growth factors.
Assuntos
Fator de Crescimento Epidérmico/metabolismo , Receptores ErbB/genética , Peptídeos/metabolismo , Sequência de Aminoácidos , Animais , Sequência de Bases , Galinhas , DNA/genética , Receptores ErbB/metabolismo , Humanos , Camundongos , Dados de Sequência Molecular , Proteínas Recombinantes/metabolismo , Homologia de Sequência do Ácido Nucleico , Especificidade da Espécie , Fatores de Crescimento TransformadoresRESUMO
Iodine-125-labeled monoclonal antibody 108.4 (108.4 mAb), raised against the extracellular domain of the epidermal growth factor (EGF) receptor, was shown to visualize sc xenografts of human oral epidermoid carcinoma (KB) cells in nude mice. In vitro, although EGF caused an increase in the number of KB cell colonies (150% at a concentration of 160 mM), the anti-EGF receptor antibodies reduced clone formation. At a concentration at which EGF caused a 50% increase in colony number, the addition of a 100-fold molar excess of 108.4 mAb resulted in a decrease in the number of cell colonies to 20% of the original value. Therefore, the effect of antibody on the KB tumor was studied in vivo in three different modes of tumor transplantation. Antitumor activity was demonstrated first by retardation (versus controls) of the growth of tumor cells as sc xenografts (P greater than .017), then by prolongation of the life span of animals with the ip form of the tumor (P less than .001), and finally on an experimental lung metastasis by a reduction in the number and size of tumors (P less than .05). When the anti-EGF receptor antibodies were added together with cisplatin, the antitumor effect was greatly enhanced, suggesting that the toxic activity of these agents is synergistic (P less than .007). The antitumor effect persisted when animals were treated with the F(ab)'2 fragment of the antibody, although it was less efficient. The Fab fragment of the antibody, whose ability to bind to the cell-associated receptor was completely conserved, did not affect the growth of the tumor. The activity manifested by the F(ab)'2 fragment of the anti-EGF receptor antibodies suggested that the antitumor effect was not due to immune mechanisms requiring the Fc portion of the antibody.
Assuntos
Anticorpos Monoclonais/uso terapêutico , Receptores ErbB/imunologia , Neoplasias Experimentais/terapia , Animais , Fragmentos Fab das Imunoglobulinas , Células KB , Camundongos , Camundongos Nus , Transplante de Neoplasias , Transplante HeterólogoRESUMO
Increased levels of epidermal growth factor receptor (EGFR) have been shown on squamous cell carcinomas. Recently, we described a squamous cell carcinoma (MH-85) derived from the oral cavity which was associated with several paraneoplastic syndromes including hypercalcemia and cachexia. This tumor induced the same paraneoplastic syndromes in nude mice (BALB/c, nu/nu, male, 4-6 weeks old). Scatchard analysis revealed that there are two classes of EGFR in MH-85. The dissociation constant and number of binding sites for the high affinity receptors were 38 pM and 5 x 10(4)/cell, respectively, and 2.2 nM and 6 x 10(5) cell, respectively, for the low affinity receptors. Growth of MH-85 in culture was stimulated by epidermal growth factor (EGF) and inhibited by monoclonal antibody 108 to human EGFR, which recognizes the extracellular domain of the EGF receptor. Surgical removal of submandibular glands from male nude mice resulted in a dramatic decrease in plasma EGF levels and a significant reduction of tumor growth, hypercalcemia, and cachexia. When EGF (5 micrograms/mouse, every 2 days for 6 weeks, i.p.) was administered to these sialoadenectomized animals, tumor growth increased, with a parallel increase in hypercalcemia. When monoclonal antibody 108 (1 mg/mouse, i.p.) was given 1, 5, and 10 days after MH-85 tumor implantation, tumor formation was retarded, which resulted in delayed onset of hypercalcemia and cachexia. Moreover, when the antibody was injected 6 times in nude mice exhibiting large tumors and profound hypercalcemia and cachexia, there was a striking decrease in tumor growth, which was accompanied with a reversal of hypercalcemia and cachexia. These results indicate that growth of the human squamous cell carcinoma MH-85 is dependent on the EGFR pathway and that subsequent development of hypercalcemia and cachexia is dependent on tumor growth. They also suggest that agents which interfere with the EGFR pathway may have therapeutic potential as anticancer agents in some human tumors.
Assuntos
Carcinoma de Células Escamosas/metabolismo , Fator de Crescimento Epidérmico/metabolismo , Receptores ErbB/metabolismo , Neoplasias do Seio Maxilar/metabolismo , Síndromes Paraneoplásicas/metabolismo , Animais , Caquexia/metabolismo , Carcinoma de Células Escamosas/patologia , Humanos , Hipercalcemia/metabolismo , Camundongos , Camundongos NusRESUMO
We recently reported the cloning and overexpression of full-length forms of human fibroblast growth factor (FGF) receptors, bek and flg. These receptors contain three immunoglobulin (Ig)-like domains and an unusual acidic motif in the extracellular region, a single transmembrane segment and a protein tyrosine kinase cytoplasmic domain containing a 14 amino acid insert. Each of the related full-length gene products interacts at high affinity with both acidic FGF and basic FGF. We now report the isolation of cDNA clones encoding two variant forms of human bek. One variant form encodes a potentially secreted bek protein containing only the first Ig-like domain and acidic motif, whereas the other variant includes all of the full-length bek protein except the first Ig-like domain and acidic motif. Overexpression of the latter bek form in NIH3T3 cells has been used to demonstrate that the N-terminal Ig-like domain and acidic region are not required for binding or activation of bek by aFGF or bFGF.
Assuntos
Fator 1 de Crescimento de Fibroblastos/metabolismo , Fator 2 de Crescimento de Fibroblastos/metabolismo , Receptores de Superfície Celular/metabolismo , Células 3T3 , Sequência de Aminoácidos , Animais , Sequência de Bases , Clonagem Molecular , Proteínas Filagrinas , Humanos , Cinética , Camundongos , Dados de Sequência Molecular , Oligodesoxirribonucleotídeos , Fosforilação , Receptores de Superfície Celular/genética , Receptores de Fatores de Crescimento de Fibroblastos , Proteínas Recombinantes/metabolismo , TransfecçãoRESUMO
AIMS: In axillary node negative (ANN) breast cancer patients additional prognostic markers are needed to decide whether adjuvant systemic treatment might be useful. METHODS: In the present study, the prognostic relevance of mitotic counts and Bloom-Richardson grade (BR-grade) was evaluated in 164 ANN breast cancer patients. No adjuvant systemic treatment was given to any of these patients. Mitotic counts were determined twice, in routine practice and in revision. RESULTS: A substantial reproducibility of mitotic counts was found, provided that the cut-off value chosen was high enough. After a median follow-up of 10 years, mitotic counts had no prognostic significance for survival at any cut-off value. A trend towards a significant worse survival was found for patients with Bloom-Richardson grade II or III in comparison with grade I. CONCLUSIONS: Based on data in the literature a positive association between both mitotic counts and BR-grade and survival in ANN breast cancer may exist, but the extent of this putative association and its clinical relevance can be argued, particularly in a group of patients with predominantly well differentiated tumours.
Assuntos
Neoplasias da Mama/patologia , Carcinoma Ductal de Mama/patologia , Linfonodos/patologia , Índice Mitótico , Idoso , Axila , Neoplasias da Mama/mortalidade , Carcinoma Ductal de Mama/mortalidade , Feminino , Seguimentos , Humanos , Pessoa de Meia-Idade , Análise Multivariada , Recidiva Local de Neoplasia/mortalidade , Recidiva Local de Neoplasia/patologia , Estadiamento de Neoplasias , Prognóstico , Estatística como Assunto , Análise de Sobrevida , Saúde da MulherRESUMO
The response of malignant and nonmalignant human breast cell lines to the growth inhibitory effects of monoclonal antibodies against the epidermal growth factor (EGF) receptor was studied. A series of human breast cell lines, which express EGF receptor, were used: MDA-468, MDA-231, and Hs578T human breast cancer cells and the transformed human mammary epithelial cell lines 184A1N4 and 184A1N4-T that have been benzo[a]pyrene immortalized and further transformed with SV40T, respectively. Four antibodies of two different classes were tested: 225 immunoglobulin G (IgG), 108.4 IgG, 96 immunoglobulin M (IgM), and 42 IgM. All four antibodies inhibited the anchorage-dependent and -independent, EGF-stimulated growth of 184A1N4 and 184A1N4-T cells, respectively, and this growth inhibition could be reversed by the addition of increasing concentrations of EGF. In contrast, the antibodies inhibited the anchorage-dependent and -independent growth of MDA-468 cells in the absence of exogenous EGF suggesting that the antibodies were acting to block access of an endogenously produced ligand to the EGF receptor. In the presence of antibody and increasing concentrations of EGF, MDA-468 cell growth was first stimulated then inhibited as the EGF concentration increased, thus, uncovering the growth stimulatory potential of low concentrations of EGF in these cells. Data is presented that indicates MDA-468 cells secrete a transforming growth factor with autocrine growth stimulatory capabilities. The growth of MDA-231 and Hs578T cells, which contain activated ras oncogenes, was not inhibited by the antibodies and the growth of these cell lines was not stimulated by EGF. Of the cell lines studied only MDA-468 cells appear to possess an autocrine growth stimulatory capacity.
Assuntos
Anticorpos Monoclonais/farmacologia , Neoplasias da Mama/patologia , Fator de Crescimento Epidérmico/farmacologia , Receptores ErbB/fisiologia , Neoplasias Hormônio-Dependentes/patologia , Anticorpos Monoclonais/imunologia , Adesão Celular , Divisão Celular/efeitos dos fármacos , Receptores ErbB/imunologia , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Humanos , Fatores de Crescimento Transformadores/metabolismo , Células Tumorais Cultivadas/efeitos dos fármacos , Células Tumorais Cultivadas/metabolismo , Células Tumorais Cultivadas/patologiaRESUMO
Very sensitive assays of IgE are required for determining prevalence of allergic reactions in children. In order to develop a sensitive two-site IRMA two kinds of mAb were produced. Antibodies specific for D epsilon 1 determinants were derived from immunization with a 40 kDa papain Fc fragment. They bound equally native and 56 degrees C heated IgE. D epsilon 2 specific mAb were obtained after immunization with IgE anti-D epsilon 1 complex and were selected on the basis of their inability to bind heated IgE. In a two-site assay on plastic plates, D epsilon 1 specific mAb led to the binding of IgE but always prevented further binding of anti-D epsilon 1 mAb, anti-human kappa chain mAb or allergen on bound IgE. This was not true when CNBr activated cellulose was used. The influence of the nature of the solid phase disappeared when D epsilon 2 specific mAb were coated on plastic tubes. In this case, the binding of a second mAb with identical or different fine specificity was observed. The best matched pair was E 164 (anti-D epsilon 2) on the solid phase and 6H10 (anti-D epsilon 1) as a tracer. As little as 0.2 UI/ml of IgE could be detected in a 2 hr test.
Assuntos
Anticorpos Monoclonais , Imunoglobulina E/análise , Animais , Especificidade de Anticorpos , Epitopos/imunologia , Feminino , Humanos , Imunoglobulina E/imunologia , Fragmentos Fc das Imunoglobulinas/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Plásticos , Conformação Proteica , RadioimunoensaioRESUMO
PURPOSE OF THE STUDY: Core decompression of the femoral head is a conservative surgical treatment with controversial efficacy. We studied retrospectively a series of 32 cases of femoral head osteonecrosis treated by core decompression between 1988 and 2000 in 25 patients. We examined the epidemiological and clinical features as well as the laboratory findings, comparing cases requiring secondary hip replacement and those who had a favorable outcome. We search for prognostic factors. MATERIAL AND METHODS: The series included 32 hips, one case was lost to follow-up. Mean age at decompression was 41.3 years (22-55). In eight hips, osteonecrosis was favored by corticosteroid treatment, in three by chronic alcoholism, and in one by hypertriglyceridemia. No favoring factors were present for 20 hips. According to the ARCO classification there were 15 stage I hips, 13 stage II, 3 stage III, and one stage IV. Core decompression was centered in 24 hips and mean time to decompression was 6.4 months (14 days to 40 months). We reviewed hips without a total prosthesis using the Postel-Merle-d'Aubigne function score and for the radiological assessment the ARCO stage and the Koo index. RESULTS: Favorable outcome was noted in 12 hips. Total hip arthroplasty was required for 19, one hip was lost to follow-up. Mean follow-up in the success group was 82 months (26-176) and mean "time of participation" in the failure group was 11 months (1-38). Mean survival after core decompression was 14 months. Time between onset of symptoms and decompression did not influence outcome. Lesions which remained asymptomatic before decompression remained stable. The stage I hips did not have more favorable outcome than the stage II hips (p < 0.05). Stage III or IV hips had unfavorable outcome. Hips with a Koo index > 40 had a poor outcome (p < 0.05). DISCUSSION: Epidemiological factors which can worsen outcome after core decompression for osteonecrosis are controversial in the literature. Early stage disease (I or II) is considered as an ideal indication for decompression, but is insufficient alone to guarantee success. As other authors, we consider that ARCO stage III and IV and a Koo index > 40 are contraindications for decompression. Improved outcome after core decompression can only be achieved by limiting indications.
Assuntos
Descompressão Cirúrgica/métodos , Necrose da Cabeça do Fêmur/cirurgia , Corticosteroides/efeitos adversos , Adulto , Alcoolismo/complicações , Feminino , Necrose da Cabeça do Fêmur/epidemiologia , Humanos , Hipertrigliceridemia/complicações , Incidência , Masculino , Pessoa de Meia-Idade , Osteonecrose/etiologia , Prognóstico , Estudos Retrospectivos , Resultado do TratamentoRESUMO
PURPOSE OF THE STUDY: Fracture of the radial head associated with elbow instability is infrequent. We report a retrospective series of floating Judet prostheses implanted for comminutive fractures of the radial head associated with elbow laxity caused either by dislocation or rupture of the medial collateral ligaments. MATERIAL AND METHODS: The series included ten patients who underwent surgery from October 1996 to September 2002 at the Amiens University Hospital. The indication for radial head prosthesis was established in the emergency setting for fracture unamendable by osteosyntheis and elbow laxity. Mean age was 48.2 years (25-69). All patients were seen at mean follow-up of 31.7 months (18-48). According to the Mason classification as modified by Johnson, all patients had type 4 fracture. A Judet radial head prosthesis with a floating metallic cup was implanted in all patients. An investigator other than the operators evaluated outcome using the Mayo Clinic criteria. RESULTS: Joint motion as measured by goniometry was: mean flexion 121degrees (90-140 degrees), mean extension deficit 20 degrees (5-60 degrees), mean pronation 45 degrees (0-85 degrees), mean supination 42.5 degrees (0-90 degrees). The Mayo clinic score was excellent in 3, good in 2, fair in 3, and poor in 2 (prosthesis dislocation in one and hung prosthesis requiring removal in one). Four patients developed periarticular ossifications compromising the final result. DISCUSSION: The floating Judet prosthesis allows optimal adaptation of the implant to anatomy and function. For us, these implants are indispensable when the radial head fracture is associated with elbow instability. The indication for prosthesis may be questionable if the non-fixed fracture is free of associated ligament injury, as suggested by the good long-term reported after simple resection. Rigorous operative technique is crucial, with careful restitution of the radial height. The quality of the result is related to the degree of capsule and ligament injury even after optimal implant positioning. Preventive treatment against periarticular ossification should be systematic.
Assuntos
Lesões no Cotovelo , Articulação do Cotovelo/cirurgia , Instabilidade Articular/etiologia , Instabilidade Articular/cirurgia , Prótese Articular , Fraturas do Rádio/complicações , Fraturas do Rádio/cirurgia , Adulto , Idoso , Articulação do Cotovelo/diagnóstico por imagem , Feminino , Humanos , Instabilidade Articular/diagnóstico por imagem , Masculino , Pessoa de Meia-Idade , Desenho de Prótese , Radiografia , Fraturas do Rádio/diagnóstico por imagem , Estudos Retrospectivos , Fatores de TempoRESUMO
The ability of monoclonal antibody (MAb 108), an immunoglobulin G (IgG)2a against the epidermal growth factor receptor (EGF-R), to interact with lung cancer cell lines was investigated. 125I-EGF bound with high affinity to non-small-cell lung cancer (NSCLC) cells, and MAb 108 inhibited specific binding of nine NSCLC cell lines in a dose-dependent manner (IC50 = 0.3-3 micrograms per ml). 125I-MAb 108 bound with high affinity (kd = 2 nM) to a single class of sites (Bmax = 70,000 per cell) using NSCLC neuroendocrine cell line NCI-H460. Specific 125I-MAb 108 binding was inhibited with high affinity by MAb 108 but not by a control antibody IgG using large-cell carcinoma cell line NCI-H1299. 125I-MAb 108 binding was not internalized at 37 degrees C using NSCLC neuroendocrine cell line NCI-H460 and adenocarcinoma cell line NCI-H23. Also, 1 microgram per ml of MAb 108 but not of a control IgG inhibited the clonal growth of NCI-H23 and squamous cell carcinoma cell line NCI-H157 in vitro. Also, MAb 108 inhibited xenograft formation of cell lines NCI-H460, NCI-H157, and NCI-H727 in nude mice in vivo. After a palpable tumor had formed using NCI-H460 cells, injection of 100 micrograms of MAb 108 (intraperitoneally three times weekly) inhibited xenograft volume in nude mice by approximately 50%. These data suggest that MAb 108 may interact with EGF receptors on lung cancer cell lines and inhibit NSCLC proliferation.
Assuntos
Carcinoma Pulmonar de Células não Pequenas/prevenção & controle , Receptores ErbB/fisiologia , Neoplasias Pulmonares/prevenção & controle , Animais , Anticorpos Monoclonais , Relação Dose-Resposta a Droga , Receptores ErbB/imunologia , Feminino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , Transplante de Neoplasias , Células Tumorais CultivadasRESUMO
Monoclonal antibodies were prepared against human thyrotropin. 13 different antibodies were characterized. Ten antibodies were of the IgG1 subclass. The affinities of the antibodies were in the range 10(9)-10(11) mol-1 X l. Four of them were specific for hTSH and did not react with hLH, hFSH, hCG or alpha hCG. Four reacted with these hormones and recognized the alpha subunit of hCG. One cross-reacted only with hFSH. The remaining four antibodies recognized the holo-hTSH only, and thus were designated as anti-conformational determinants. Monoclonal antibodies reacting with different antigenic determinants on the hTSH molecule defined seven clusters. Two of them were used to develop a simplified two-site sandwich radioimmunoassay in which one monoclonal antibody was immobilized on tubes (anti-beta TSH) and another (anti-alpha) labelled with 125I. This assay was highly specific and demonstrated a sensitivity level of 0.1 microIU/ml. Two monoclonal antibodies were used in immunohistochemistry and their quality and specificity was assessed in the detection of hTSH immunoreactivity in human pituitary biological sections.
Assuntos
Anticorpos Monoclonais , Radioimunoensaio/métodos , Tireotropina/sangue , Anticorpos Monoclonais/isolamento & purificação , Especificidade de Anticorpos , Gonadotropina Coriônica/sangue , Reações Cruzadas , Histocitoquímica , Humanos , Hipertireoidismo/sangue , Hipotireoidismo/sangue , Radioisótopos do Iodo , Conformação ProteicaRESUMO
During HIV infection the architecture of secondary lymphoid tissues is severely disrupted. In particular the germinal centers, which play a key role in the orchestration of the secondary immune response, undergo gross phenotypic alterations, leading to a complete destruction of the germinal center microenvironment. The precise mechanisms responsible for the lymphoid tissue destruction in HIV infection are still unknown. However, the large influx of CD8+ T lymphocytes suggests an important role for T cell-mediated cytotoxicity. To establish whether the infiltrating CD8+ T lymphocytes are killing competent, we investigated the expression of granzyme B, which is known to be present in the cytotoxic granules of NK cells and "activated" CTLs with cytolytic potential. We observed a 20-fold increase in the percentage of granzyme B-expressing CD8+ T cells in both the germinal center and the interfollicular areas in HIV patients relative to HIV-negative controls. This increase was present in patients with early-stage disease (i.e., absolute CD4+ T cell count > 500/microliters) as well as in patients with intermediate and late-stage disease. Thus, from relatively early stages of HIV infection onward large numbers of killing competent T lymphocytes are present in the lymphoid tissues, a finding that supports the notion that CTL act as mediators of destruction of immune function during HIV infection.
Assuntos
Infecções por HIV/enzimologia , Linfonodos/enzimologia , Serina Endopeptidases/metabolismo , Linfócitos T Citotóxicos/enzimologia , Adulto , Idoso , Feminino , Granzimas , Infecções por HIV/sangue , Humanos , Imuno-Histoquímica , Lactente , Linfonodos/citologia , Masculino , Pessoa de Meia-IdadeRESUMO
PURPOSE OF THE STUDY: We report our experience with 25 peri-lunate posterior wrist dislocations and compare outcome with data in the literature searching for prognostic factors. MATERIAL AND METHODS: Our series included 24 men and one woman, mean age 36 years. Twenty-three patient were less than 50 years old at the time of the accident. Diagnosis was established late in five patients. All patients were reviewed clinically and radiologically with a mean follow-up of 57 months. We differentiated pure dislocations (n=16) from trans-scapho-lunate dislocations (n=9). The pure dislocations included six type 1 and ten type 2 in the Witvoët and Allieu classification. We also distinguished groups by open or closed treatment, with or without pinning, and with or without suture of the scapho-lunate ligament. Screw fixation was used in case of scaphoid fracture. Post-operative cast immobilization was 45 days on the average, followed by three months of rehabilitation exercises. RESULTS: Residual pain of variable intensity was reported by 22 patients but subjectively, 21 patients considered outcome to be good or very good. Wrist movement was greatly impaired in eight patient with a 60 degrees flexion-extension arc. All patients had a 20% reduction in force compared with the healthy side. According to the Green and O'Brian functional score, outcome was poor in four wrists. The scapholunate space and the sapholunate angles were abnormal in seven wrists. Reduction was insufficient in only one case with the scapholunate space measuring 5 mm after trans-scapho-lunate dislocation. In most of the cases, these poor functional and/or radiographic results coincided with carpal instability which developed early or late after trauma. The most bothersome element in other cases was wrist stiffness. The trans-scapho-lunate dislocations appeared to evolve more favorably than the pure dislocations, but could also cause carpal instability. DISCUSSION: There is a real functional impairment after posterior peri-lunate dislocation. The differences in outcome we observed were not statistically correlated with type of treatment, probably because of the small number of patients, but did reveal certain tendencies. Closed reduction did not always avoid the development of carpal instability and gave only average results. Percutaneous pinning or open reduction did not improve outcome in pure dislocations. It might be good to use scapho-lunate suture more often to obtain better healing and reduce the risk of carpal instability, as has been suggested by certain teams.
Assuntos
Luxações Articulares , Articulação do Punho , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Seguimentos , Humanos , Luxações Articulares/diagnóstico por imagem , Luxações Articulares/cirurgia , Osso Semilunar , Masculino , Pessoa de Meia-Idade , Radiografia , Fatores de TempoRESUMO
Recent evidence shows that different fibroblast growth factors (FGF) bind with similar high affinities to two FGF receptors (FGFR) called flg and bek. In order to explore the mechanism of FGFR tyrosine autophosphorylation, we have generated cell lines which co-express a kinase-negative mutant of FGFR and an active form of FGFR. The following transfected NIH 3T3 cells were generated: (i) cells which express a shorter truncated form of bek (two Ig domains) together with a kinase-negative mutant of full length bek (bek K517A), (ii) cells which express wild-type bek together with kinase-negative flg (flg K514A) and (iii) cells co-expressing wild-type flg together with bek K517A. Immunoprecipitations with either bek-or flg-specific antisera followed by immunoblotting indicated that the double transfectants express the desired receptor species. The addition of acidic FGF (aFGF) to the various cell lines followed by immunoprecipitation with anti-FGFR antibodies and immunoblotting with anti-phosphotyrosine specific antibodies indicated that aFGF induces tyrosine phosphorylation of the kinase-negative FGFR mutants. These results show that tyrosine autophosphorylation of the kinase-negative FGFR is mediated by a transphosphorylation mechanism and that both homologous (bek----bek) and heterologous (bek----flg and flg----bek) transphosphorylation occurs in living cells. Recent evidence shows that tyrosine autophosphorylation of receptors with tyrosine kinase activities is essential for mediating interactions with signaling molecules. Therefore, heterologous transphosphorylation could amplify the response of cells to various forms of FGFs and their cognate receptors.
Assuntos
Fatores de Crescimento de Fibroblastos/metabolismo , Receptores de Superfície Celular/metabolismo , Sequência de Bases , Western Blotting , Reações Cruzadas , Eletroforese em Gel de Poliacrilamida , Proteínas Filagrinas , Vetores Genéticos , Humanos , Higromicina B/metabolismo , Ligantes , Dados de Sequência Molecular , Fosforilação , Testes de Precipitina , Receptores de Fatores de Crescimento de Fibroblastos , Transfecção , Tirosina/metabolismoRESUMO
The epidermal growth factor receptor (EGF-R) and the erbB-2 proto-oncogene product protein are closely related by their structural homology and their shared enzymatic activity as autophosphorylating tyrosine kinases. We show that in mammary tumor cells (SK-BR-3) EGF causes a rapid increase in tyrosine phosphorylation of the erbB-2 protein. Phosphorylation of erbB-2 does not occur in cells lacking the EGF-R (MDA-MB-453). Phosphorylation of erbB-2 in SK-BR-3 cells is blocked if EGF is prevented from interacting with its receptor by specific monoclonal antibodies. While EGF induces the down-regulation of its receptor in SK-BR-3 cells, EGF has no effect on the stability of the erbB-2 protein. This result suggests that the erbB-2 protein is a substrate of the EGF-R and indicates the possibility of communication between these two proteins early in the signal transduction process.
Assuntos
Neoplasias da Mama/patologia , Fator de Crescimento Epidérmico/metabolismo , Receptores ErbB/metabolismo , Proteínas Proto-Oncogênicas/metabolismo , Tirosina/metabolismo , Neoplasias da Mama/metabolismo , Humanos , Fosforilação , Processamento de Proteína Pós-Traducional , Proteínas Tirosina Quinases/metabolismo , Proto-Oncogene Mas , Receptor ErbB-2 , Células Tumorais CultivadasRESUMO
The epidermal growth factor (EGF) receptor is a transmembrane glycoprotein composed of a large extracellular ligand-binding region connected to the cytoplasmic kinase domain by a single transmembrane (TM) region. To explore the role of the TM region in the process of receptor activation, we have generated EGF-receptor mutants with altered TM regions by utilizing in vitro site-directed mutagenesis. The TM regions of two mutant receptors were either extended (designated i626-3) or shortened (designated d625.3) by three hydrophobic amino acid residues. In the other two mutant receptors, hydrophobic amino acids were substituted by charged residues--i.e., Val-627 was replaced by glutamic acid (designated V627E) or Leu-642 was replaced by an arginine residue (designated L642R). NIH 3T3 cells lacking endogenous EGF receptors were transfected with constructs encoding either wild-type or mutant receptors and shown to express the receptor molecules using 125I-labeled EGF binding and immunoprecipitation experiments. The mutant receptors were expressed on the cell surface as polypeptides of Mr 170,000 exhibiting typical high- and low-affinity binding sites for 125I-labeled EGF. Similar to its effect on wild-type receptors, phorbol 12-myristate 13-acetate abolished the mutant-receptor high-affinity binding sites for EGF. Moreover, EGF was able to stimulate the kinase activities of wild-type and mutant receptors both in vitro and in living cells. The mutant receptors were also able to undergo EGF-induced receptor dimerization as revealed by cross-linking experiments with a bifunctional covalent cross-linking agent. These results are compatible with an intermolecular allosteric oligomerization model for receptor activation rather than with a model based on an intramolecular mechanism for receptor activation.